Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Inventory (2021 - 2025)

Apellis Pharmaceuticals has reported Change in Inventory over the past 5 years, most recently at $8.7 million for Q4 2025.

  • Quarterly results put Change in Inventory at $8.7 million for Q4 2025, up 186.4% from a year ago — trailing twelve months through Dec 2025 was $15.3 million (up 41.95% YoY), and the annual figure for FY2025 was $15.3 million, up 41.95%.
  • Change in Inventory for Q4 2025 was $8.7 million at Apellis Pharmaceuticals, up from -$5.4 million in the prior quarter.
  • Over the last five years, Change in Inventory for APLS hit a ceiling of $47.8 million in Q4 2023 and a floor of -$14.0 million in Q1 2025.
  • Median Change in Inventory over the past 5 years was $12.9 million (2022), compared with a mean of $9.4 million.
  • Biggest five-year swings in Change in Inventory: surged 10461.81% in 2024 and later plummeted 193.81% in 2025.
  • Apellis Pharmaceuticals' Change in Inventory stood at $14.6 million in 2021, then soared by 77.33% to $26.0 million in 2022, then soared by 84.18% to $47.8 million in 2023, then tumbled by 120.96% to -$10.0 million in 2024, then skyrocketed by 186.4% to $8.7 million in 2025.
  • The last three reported values for Change in Inventory were $8.7 million (Q4 2025), -$5.4 million (Q3 2025), and $26.0 million (Q2 2025) per Business Quant data.